|
Synonyms: APN-311 | Ch14.18 | MAb-14.18 | Unituxin®
dinutuximab is an approved drug (FDA (2015))
Compound class:
Antibody
Comment: Dinutuximab is a chimeric mouse/human monoclonal antibody targeting ganglioside-GD2.
Annotated peptide sequences for this antibody are available from its IMGT/mAb-DB record. A patent search identifies US20140170155 [4] as the applicable patent. US20140170155 reveals APN311 as a formulation of the mouse-human chimeric anti-GD2 antibody ch14.18 recombinantly produced in Chinese hamster ovary (CHO) cells. Efficacy of the preferred antibody was determined by its cytolysis capacity in GD2-expressing cells, as determined by a complement dependent cytolysis assay. |
Classification  |
|
| Compound class | Antibody |
| Approved drug? | Yes (FDA (2015)) |
| International Nonproprietary Names |
|
| INN number | INN |
| 9754 | dinutuximab |
| Synonyms |
| APN-311 | Ch14.18 | MAb-14.18 | Unituxin® |
| Database Links |
|
| Specialist databases | |
| IMGT/mAb-DB | 464 |
| Other databases | |
| GtoPdb PubChem SID | 249565662 |
| Search PubMed clinical trials | dinutuximab |
| Search PubMed titles | dinutuximab |
| Search PubMed titles/abstracts | dinutuximab |
| Wikipedia | Dinutuximab |
